Sabrina Green and colleagues published a retrospective observational study of 12 cases of expanded access customized phage therapy. They found that customized phage production and therapy was safe and yielded favorable clinical or microbiological outcomes in 2/3 of cases. They suggest that a center dedicated to tailoring the phages against a patient’s specific infection may be a viable option.